ReviewDiscover nano2026
Nanodrug delivery systems enhance traditional Chinese medicine treatment of osteoporosis.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Osteoporosis (OP) is a prevalent chronic metabolic bone disorder characterized by decreased bone mineral density, deterioration of bone microarchitecture, and increased fracture risk. Traditional Chinese medicines (TCM) have demonstrated considerable therapeutic potential in OP management due to their osteogenic and anti-resorptive activities. However, the therapeutic efficacy of TCM is often limited by the drawbacks of conventional delivery systems, underscoring the need for advanced formulation strategies to fully exploit their potential in OP prevention and treatment. In recent years, nanomedicine has emerged as a transformative platform for drug delivery, offering new avenues to enhance the pharmacological performance of herbal medicines. Nano-based delivery systems for anti-osteoporotic herbal compounds provide multiple benefits, including protection of active ingredients from degradation, improved bioavailability, reduced gastrointestinal irritation, and superior therapeutic outcomes. This review provides a comprehensive overview of the nanocarriers employed in the delivery of TCM, summarizes the current status and therapeutic efficacy of herb-loaded nanomedicines in OP management, and discusses the challenges and future directions for clinical translation. By highlighting recent advances and addressing existing hurdles, this review aims to contribute valuable insights for optimizing TCM-based nanotherapeutics in the prevention and treatment of osteoporosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.